Management of ocular manifestations of Behcet's disease: outcome with cytotoxic drugs
- 8 August 2005
- journal article
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 8 (2), 119-123
- https://doi.org/10.1111/j.1479-8077.2005.00139.x
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- New and innovative therapies for Behcet's diseaseInternational Journal of Rheumatic Diseases, 2004
- Comparative analysis of Behcet's disease in the APLAR regionInternational Journal of Rheumatic Diseases, 2004
- Infliximab in the treatment of refractory posterior uveitisOphthalmology, 2003
- The Effect of Anti-Tumour Necrosis Factor alpha (Infliximab) on Sight-Threatening Uveitis in a Patient with Behçet’s DiseasePublished by Springer Nature ,2002
- Successful Long-term Treatment of Refractory Adamantiades-Behçet’ss Disease (ABD) with Infliximab: Report of Two PatientsPublished by Springer Nature ,2002
- The Use of Interferon-α in Behçet’s Disease — Review of the Literature and Possible Mechanisms of ActionPublished by Springer Nature ,2002
- The Influence of the Delay of Aggressive Treatment on the Vision and its Outcome in Behçet’s DiseasePublished by Springer Nature ,2002
- Anti-tumour necrosis factor monoclonal antibody treatment for ocular Behcet's diseaseAnnals Of The Rheumatic Diseases, 2002
- Long-Term Effects of Interferon Alpha 2A Treatment in Behçet’s DiseaseDermatology, 2000
- Behçet's syndrome: Treatment with recombinant leukocyte alpha-interferonArchives of Dermatological Research, 1986